Pharmacometrics & Pharmacokinetics (PMK) Community

Community Goals

Scientific Expertise:
  • The PMK Community is a unique resource to learn about newer applications of pharmacometrics and pharmacokinetics and best practices via programming, webinars and white papers enabled by participation of members with diverse interests (pharmacokineticists, statistical pharmacometricians, PBPK experts, transporter experts from industry, academia, and regulatory, and student/trainees).
Catalyst for Innovation:
  • Hosts educational forums to promote emerging areas of influence by thought-leaders. Also contributes to establishing point-counterpoint formats to discuss hot topics to enhance the attendee experience at Annual Meetings.
Influence and Impact:
  • Currently working to identify at least one focus area for which a concept outline will be developed for a Best Practice White Paper followed by 2-year goal to publish an article.
Education and Communication:
  • The PMK Community is exploring opportunities to set up a model library to capture pertinent technical information to supplement information in published articles from select journals. PMK is also active on social media will ensuring frequent communication with members.
Organizational Effectiveness:
  • PMK has established Steering Committee membership along with general roles & expectations necessary to align with contributions with other Community goals. The Community is also developing a communication outreach plan to Community members to announce key dates and news updates.

Join the LinkedIn Group.

Upcoming Webinar
ASCPT Members-Only Webinar presented by the Pharmacometrics & Pharmacokinetics (PMK) Community
Title:  Tisagenlecleucel Modelā€Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
Date and Time: Tuesday, December 10, 2019, 1:00 pm ET
Speakers: Andy Stein, PhD, and Edward Waldron, MSc, PhD
Moderator: Neeraj Gupta, PhD
Description: Novel modalities of immuno-oncology agents such as CAR-T therapies have now started to take main stage in the era of post immune checkpoint agents. With the approval of two CAR-T therapies and several hundred ongoing clinical trials, clinical pharmacology and pharmacometrics considerations have not only become important to understand the mechanism of action, but also to support development and registrational questions such as dose and impact of various intrinsic and extrinsic factors. This special presentation will focus on kinetics of Tisagenlecleucel, an approved CD19 directed CAR-T therapy, and assess the impact of intrinsic and extrinsic factors, with a focus on comedications used for treating cytokine release syndrome.
Registration Link: 

Past Webinars

Sree Kasichayanula, PhD

Community Chair


Chunze Li, PhD

Community Vice Chair


Michael A. Tortorici, PharmD, PhD

Community Past Chair


Steering Committee

Neeraj Gupta, PhD
Chao Liu, PhD
Robert Bies, PharmD, PhD
Hechun Wang, MS
Xiaoying Chen, PhD
Chunze Li, PhD
Michael Tortorici, PharmD, PhD
Photo Gallery
Recent News
Contact Us